PaxVax Gets $62M For Vaccine Efforts

Redwood City-based PaxVax, a developer of vaccines for infectious disease, has raised $62M in funding, split between $50M in secured debt financing and $12M in an extension of its Series B funding round. The company said the debt financing came from an investment fund managed by Pharmakon Advisors. The funding will go towards acquisition of a FDA-approved, oral typhoid vaccine from Crucell Switzerland AG, as well as clinical development, regulatory review, and launch of a vaccine for cholera. More information »